![]()
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Rational pharmacoeconomics?
As part of an information campaign—presumably to push
down the manufacturer’s proposed price increase of metoprolol succinate
(New Zealand's most preferred beta-blocker)—PHARMAC sent a four-page
letter to general practitioners (GPs) outlining various options for changing
medications in order to “ free up money for new drug investments.”
One option mentioned is to change patients from metoprolol
succinate to carvedilol.
If GPs swap everybody on metoprolol succinate plus any
diuretic or person with a hint of puffy ankles (i.e. with possible congestive
heart failure) onto carvedilol, is PHARMAC better off or worse off financially?
Is the patient better off or worse off financially or
physically as they return to the General Practice for blood pressure monitoring
and titration changes? Is the General Practice supposed to absorb the nurses and
doctors time costs because of increased patient benefits being rolled out on 1
July 2007? Is this a legitimate patient charge? Should the prescription for
carvedilol be 3 months stat or 1 month and two repeats endorsed close control?
Should the changed script be for 1 month only and require the patient to return
to the General Practice and pay another fee for monitoring and review?
Is the pharmacist going to cost more in the short term or
the long term to the patient or to the taxpayer? Carvedilol is nominally three
times the price of metoprolol succinate according to the Pharmaceutical
Schedule?
Is there a cap on the number of prescriptions for carvedilol
before PHARMAC starts to see a heavy reduction in price per tablet? Where is the
break-even point? Are GPs supposed to choose to change medications on the basis
of the cost to the patient in part charges; the nominal drug cost to PHARMAC;
the improved profit margin to the chemist; the increased services to the General
Practice; the evidence for the particular drug in the literature; or what?
Who should benefit financially from the change and who
should pay directly and indirectly for the changes to be implemented?
And how are GPs supposed to make a rational decision?
Bill Douglas
GP Wanganui |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Current
issue | Search journal |
Archived issues | Classifieds
| Hotline (free ads) Subscribe | Contribute | Advertise | Contact Us | Copyright | Other Journals |